BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 32259795)

  • 41. Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-β-D-glucoside in doxorubicin-resistant human leukemia K562/DOX.
    Wang TX; Shi XY; Cong Y; Wang SG; Wang YY; Zhang ZQ
    Indian J Pharmacol; 2013; 45(6):597-602. PubMed ID: 24347768
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vielanin P enhances the cytotoxicity of doxorubicin via the inhibition of PI3K/Nrf2-stimulated MRP1 expression in MCF-7 and K562 DOX-resistant cell lines.
    Gao HL; Xia YZ; Zhang YL; Yang L; Kong LY
    Phytomedicine; 2019 May; 58():152885. PubMed ID: 31009836
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Selection of P-Glycoprotein Inhibitor and Formulation of Combinational Nanoformulation Containing Selected Agent Curcumin and DOX for Reversal of Resistance in K562 Cells.
    Dash TK; Konkimalla VB
    Pharm Res; 2017 Aug; 34(8):1741-1750. PubMed ID: 28536971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of saikosaponin D on doxorubicin pharmacokinetics and its MDR reversal in MCF-7/adr cell xenografts.
    Li C; Xue HG; Feng LJ; Wang ML; Wang P; Gai XD
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4437-4445. PubMed ID: 29077148
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
    Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
    Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells.
    Chen Y; Zhao Y; Wang C; Xiao X; Zhou X; Xu G
    Med Sci Monit; 2012 Oct; 18(10):BR383-8. PubMed ID: 23018344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multifunctional PLGA nanoparticles combining transferrin-targetability and pH-stimuli sensitivity enhanced doxorubicin intracellular delivery and in vitro antineoplastic activity in MDR tumor cells.
    Scheeren LE; Nogueira-Librelotto DR; Mathes D; Pillat MM; Macedo LB; Mitjans M; Vinardell MP; Rolim CMB
    Toxicol In Vitro; 2021 Sep; 75():105192. PubMed ID: 33984456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual P-Glycoprotein and CA XII Inhibitors: A New Strategy to Reverse the P-gp Mediated Multidrug Resistance (MDR) in Cancer Cells.
    Teodori E; Braconi L; Bua S; Lapucci A; Bartolucci G; Manetti D; Romanelli MN; Dei S; Supuran CT; Coronnello M
    Molecules; 2020 Apr; 25(7):. PubMed ID: 32290281
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of P-glycoprotein and its inhibitors on apoptosis in K562 cells.
    Zu Y; Yang Z; Tang S; Han Y; Ma J
    Molecules; 2014 Aug; 19(9):13061-75. PubMed ID: 25157469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pH-sensitive amphiphilic chitosan-quercetin conjugate for intracellular delivery of doxorubicin enhancement.
    Mu Y; Wu G; Su C; Dong Y; Zhang K; Li J; Sun X; Li Y; Chen X; Feng C
    Carbohydr Polym; 2019 Nov; 223():115072. PubMed ID: 31427010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination of Protoporphyrin IX-mediated Sonodynamic Treatment with Doxorubicin Synergistically Induced Apoptotic Cell Death of a Multidrug-Resistant Leukemia K562/DOX Cell Line.
    Wang X; Jia Y; Su X; Wang P; Zhang K; Feng X; Liu Q
    Ultrasound Med Biol; 2015 Oct; 41(10):2731-9. PubMed ID: 26166458
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake.
    Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J
    Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comb-like amphiphilic polypeptide-based copolymer nanomicelles for co-delivery of doxorubicin and P-gp siRNA into MCF-7 cells.
    Suo A; Qian J; Zhang Y; Liu R; Xu W; Wang H
    Mater Sci Eng C Mater Biol Appl; 2016 May; 62():564-73. PubMed ID: 26952460
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox].
    Zhou JH; Wu DZ
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):81-5. PubMed ID: 15946544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance.
    Qiu Q; Zhou J; Shi W; Kairuki M; Huang W; Qian H
    Bioorg Chem; 2019 May; 86():166-175. PubMed ID: 30710850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
    Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
    Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Reversal of mdrl gene-dependent multidrug resistance in multidrug resistance human leukemia cell line K562/ADM using short hairpin RNA expression vectors].
    Gan HZ; Zhang GZ; Lu ZX; Pu LS; Yang SJ; Gao S; Zheng DM
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jun; 28(6):383-7. PubMed ID: 17939403
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
    Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
    J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel curcumin derivatives as P-glycoprotein inhibitors: Molecular modeling, synthesis and sensitization of multidrug resistant cells to doxorubicin.
    Sagnou M; Novikov FN; Ivanova ES; Alexiou P; Stroylov VS; Titov IY; Tatarskiy VV; Vagida MS; Pelecanou M; Shtil AA; Chilov GG
    Eur J Med Chem; 2020 Jul; 198():112331. PubMed ID: 32403017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.